EP. 5: OAB Treatment: Available Strategies and Rationale for Use

Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.

Sponsored by AbbVie US Medical Affairs

EP: 1.In-Clinic Educational Resource on the OAB Treatment Pathway

EP: 2.EP. 1: An Introduction of the Speakers

EP: 3.EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations

EP: 4.EP. 3: The Typical Patient with OAB and Common Signs and Symptoms

EP: 5.EP. 4: The Role of Urodynamic Testing in OAB Evaluation

Now Viewing

EP: 6.EP. 5: OAB Treatment: Available Strategies and Rationale for Use

EP: 7.EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB

EP: 8.Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies

EP: 9.EP. 8: Patient-Clinician Conversations Regarding Initial Pharmacologic Treatment for OAB

EP: 10.EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB

EP: 11.EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making

EP: 12.EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies

EP: 13.EP. 12: OAB Patient Monitoring and Followup Considerations in the Third-Line Treatment Setting

EP: 14.EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA

EP: 15.EP. 14: SNM and PTNS for OAB: Device Management and Followup

EP: 16.EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB

This content is intended for US/PR Healthcare Professionals.

The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.